Core Viewpoint - The stock of Meihao Medical (301363) has shown a positive performance with a closing price of 31.94 yuan on February 3, 2026, reflecting a 4.01% increase, while the company has experienced mixed financial results in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28% [3]. - The net profit attributable to shareholders was 208 million yuan, representing a year-on-year decrease of 19.25% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, with a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 18.17 billion yuan, ranking 15th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 65.45, which is lower than the industry average of 97.37, ranking 62nd [3]. - The company's gross margin stands at 39.34%, below the industry average of 50.55%, ranking 89th [3]. Capital Flow Analysis - On February 3, 2026, the net inflow of main funds was 15.54 million yuan, accounting for 5.09% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on February 2 and January 30, 2026 [2]. Institutional Ratings - In the last 90 days, seven institutions have rated Meihao Medical with a "buy" recommendation, with an average target price of 24.57 yuan [4].
股票行情快报：美好医疗（301363）2月3日主力资金净买入1553.92万元